{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Heart rate <44 bpm"},{"categories":[{"measurements":[{"groupId":"OG000","value":"66"}]}],"title":"Heart rate 44 to 100 bpm"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}],"title":"Heart rate 101 to 120 bpm"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Heart rate>120 bpm"}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"}],"units":"Participants"}],"description":"Heart rate is the measure of heart beats per minute (bpm). The number of participants with a post-Baseline shift from Baseline in heart rate of \\<44 bpm, 44 to 100 bpm, 101 to 120 bpm, and \\>120 bpm was assessed.","groups":[{"description":"Participants received pazopanib 800 milligrams (mg) once daily.","id":"OG000","title":"Pazopanib 800 mg"}],"paramType":"NUMBER","populationDescription":"ATS Population. Only those participants available at the specified time points were analyzed.","reportingStatus":"POSTED","timeFrame":"From Baseline to investigational product discontinuation (up to 6.230 years)","title":"Number of Participants With the Indicated Shift in Heart Rate From Baseline at Any Time Post-Baseline","type":"PRIMARY","unitOfMeasure":"participants"}